Protagonist Therapeutics Inc

16 de out. de 2026, 20:02 UTC

Protagonist Therapeutics Inc shares are sharply lower, diverging from a recent trend of higher daily closes, with unusually high market volume today.

15 de out. de 2026, 19:46 UTC

UBS has initiated a Buy rating on Protagonist Therapeutics Inc with a price target of $184, highlighting the commercial potential of PN-881.

14 de out. de 2026, 20:07 UTC

PTGX declines after Leerink initiates coverage with outperform rating.

13 de out. de 2026, 20:02 UTC

Protagonist Therapeutics Inc shares fell sharply, diverging from recent upward momentum, with unusually high trading volume observed today.

12 de out. de 2026, 20:06 UTC

Protagonist Therapeutics receives a Buy rating from UBS with a $184 price target, while Leerink Partners sets an Outperform rating with a $190 target.

9 de out. de 2026, 22:21 UTC

Protagonist Therapeutics Inc shares traded modestly lower during after-market hours on Friday after peaking shortly after the regular session ended.

8 de out. de 2026, 20:07 UTC

Protagonist Therapeutics Inc shares fell amid a broadly lower market, trading near the lower end of its one-month range and below its 20-day moving average.

7 de out. de 2026, 20:01 UTC

Protagonist Therapeutics Inc is trading higher, influenced by gains in the Biotechnology sector, despite pulling back from earlier session highs and high market volume.

6 de out. de 2026, 20:07 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining near the lower end of their one-month range and below the 20-day moving average.

1 de out. de 2026, 20:07 UTC

Protagonist Therapeutics Inc shares fell as the broader market continued its decline, marking four consecutive days of lower closes and remaining below the 20-day moving average.

30 de set. de 2026, 20:07 UTC

Protagonist Therapeutics Inc shares fell sharply after peaking earlier in the day, finishing below its 20-day moving average and near the lower end of its one-month range.

29 de set. de 2026, 19:15 UTC

Protagonist Therapeutics Inc shares fell, now near the low end of their one-month range, despite a user reporting a price target in the low $130s.

25 de set. de 2026, 19:51 UTC

Protagonist Therapeutics Inc shares are advancing significantly, showing strong upward momentum with notable trading activity since Thursday's close.

24 de set. de 2026, 19:46 UTC

Protagonist Therapeutics Inc shares fell sharply, reaching a low before noon and trading significantly below its 20-day moving average amid ongoing biotechnology sector weakness.

23 de set. de 2026, 20:02 UTC

Protagonist Therapeutics Inc shares fell sharply, continuing a decline since Tuesday, with trading volume unusually high and prices near the lower end of their one-month range.

18 de set. de 2026, 20:06 UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

17 de set. de 2026, 19:46 UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

16 de set. de 2026, 19:13 UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

15 de set. de 2026, 20:07 UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

11 de set. de 2026, 20:08 UTC

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

9 de set. de 2026, 20:07 UTC

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2 de set. de 2026, 20:08 UTC

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

1 de set. de 2026, 19:36 UTC

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

28 de ago. de 2026, 20:02 UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

27 de ago. de 2026, 20:07 UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

26 de ago. de 2026, 20:08 UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

25 de ago. de 2026, 23:36 UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

24 de ago. de 2026, 20:06 UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

21 de ago. de 2026, 20:06 UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

20 de ago. de 2026, 19:31 UTC

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.